Organism: Homo sapiens
Gene: Q9C0K0
Selected probe(set): 222895_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q9C0K0 (222895_s_at) across 5610 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-6.083145
Number of Samples:5 / 29

Experimental	precursor-B-ALL study 3 (MLL-rearranged)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	T-ALL study 3
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):-5.7850504
Number of Samples:4 / 13

Experimental	precursor-B-ALL study 2 (MLL-rearranged)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control	T-ALL study 2
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Dutch Childhood Oncology Group (DCOG).

Relative Expression (log2-ratio):-5.7693663
Number of Samples:6 / 29

Experimental	precursor-B-ALL study 3 (PAX5-rearranged)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [dic(9;20)(p11-13;q11) )/PAX5 rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	T-ALL study 3
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):-5.712145
Number of Samples:4 / 29

Experimental	precursor-B-ALL study 3 (BCR-ABL)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(9;22)(q34;q11.2)/BCR-ABL1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	T-ALL study 3
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):-5.3392706
Number of Samples:11 / 5

Experimental	kidney transplantation study 11 (1 week)
	Whole blood samples derived from kidney transplant patients 1 week post-transplantation. Samples were collected 1 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control	normal blood sample
	Blood samples derived from healthy control subjects.

Relative Expression (log2-ratio):-5.3353987
Number of Samples:17 / 29

Experimental	precursor-B-ALL study 3 (hyperdiploid)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	T-ALL study 3
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):-5.073146
Number of Samples:4 / 4

Experimental	B-CLL study 11 (rolipram)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control	rolipram study 4 (normal T-cell; 20uM)
	MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

Relative Expression (log2-ratio):-4.976259
Number of Samples:2 / 13

Experimental	precursor-B-ALL study 2 (E2A-PBX1)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control	T-ALL study 2
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Dutch Childhood Oncology Group (DCOG).

Relative Expression (log2-ratio):-4.8821726
Number of Samples:4 / 4

Experimental	B-CLL study 11 (DMSO)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control	vehicle (DMSO) treated normal T-cell sample
	MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

Relative Expression (log2-ratio):-4.455106
Number of Samples:27 / 13

Experimental	precursor-B-ALL study 2 (hyperdiploid)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control	T-ALL study 2
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Dutch Childhood Oncology Group (DCOG).